Markets Indicate Champignon Brands Inc. (CSE:SHRM) Could Pay Off

After a long and eventful history, psychedelics are finally emerging as a potential treatment for various conditions, including depression. Over the past few years, psychedelics have shaken off the trauma of the Schedule I tag that the US imposed on it in 1971. Researchers reveal that psychedelics have immense medicinal potential, and physicians and patients are willing to give it a try. 

Nowhere has the psychedelics sector gotten more traction than in North America. Numerous companies have stepped up to plug the gap in research and supply of psychedelics. Champignon Brands Inc. (CSE: SHRM) is one of the companies spearheading the foray into psychedelics in North America. 

Champignon is among the first crop of companies that are keen on exploiting the commercial aspect of psychedelics. As a testimony to this sector’s profit potential, Champignon floated its shares on the Canadian Stock Exchange (CSE) in late February 2020. Less than two months after trading commenced, the SHRM stock was up 629% to C$1.73.

On the road to the peak of the market 

A few things come to mind that informs the remarkable run of Champignon’s stock. In a bid to strengthen the management and implementation of its vision, the company hired Dr. Roger McIntyre as its CEO in mid-May. Pharmacology and Psychiatry Professor, Dr. McIntyre, is an invaluable asset to Champignon. Dr. McIntyre’s knowledge enabled the Vancouver-based company to push further into the development of “rapid-onset treatments for persons with mood disorders.”

Another critical development at the center of Champignon’s growth potential is a couple of acquisitions the company has made. The company acquired 75% of CRTCE (the Canadian Rapid Treatment Centre of Excellence). CRT has a huge portfolio of research publications specializing in the rapid-onset treatment of mood disorders. 

Besides, Champignon is in advanced stages concerning the takeover of the Wellness Clinic of Orange County Inc. (WCOOC). WCOOC is a ketamine infusion treatment entity operating out of a campus of Mission Hospital in Laguna Beach, California. This acquisition gives Champignon a permanent foothold in the United States.

Champignon has also revealed a new company name. Going forward, the company intends to be known as Apotheosis Scientific Ltd. Although the management has not specified the date for affecting the name-change, this is a clear indication that the company has a firm grip on its vision. And there is potential to achieve even greater success.

Psychedelics sector is fledgling but with great potential 

The psychedelics sector is fledgling but with an evident desire to explode soon. According to a Forbes article, the mushroom industry has long been maligned, but this is changing. The most unambiguous indication to this effect is PsyTech. PsyTech is a forum that intends to bring together researchers and investors interested in psychedelic science. 

And the equities market is responding to this psychedelic phenomenon. According to a BCC Research cited by Forbes, the global mental health medications market was valued at $88.3 billion in 2015. However, the antidepressant drug sub-sector is projected to grow the fastest. By 2023, Allied Market Research expects the antidepressant drugs market to clock $15.98 billion. The psychedelics sector presents an unpassable opportunity for investors.